A nationwide collaborative study on the long-term effects of bromocriptine in patients with parkinson’s disease: The fourth interim report

European Neurology

Volumn 31, Issue , 1991, Pages 3-16

  Nakanishi, T ^a   Mizuno, Yoshikuni ^b   Goto, I ^c   Iwata, M ^d   Kanazawa, I ^e   Kowa, H ^f   Mannen, T ^b   Nishitani, H ^g   Ogawa, N ^h   Takahashi, A ⁱ   Tashiro, K ^j   Tohgi, H ^k   Yanagisawa, N ^l  

^a Department of Neurology Mishuku Hospital ^*  (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e UNIVERSITY OF TSUKUBA   (Japan)

^f KITASATO UNIVERSITY HOSPITAL   (Japan)

^g UTANO NATIONAL HOSPITAL   (Japan)

^h OKAYAMA UNIVERSITY   (Japan)

ⁱ NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j HOKKAIDO UNIVERSITY   (Japan)

^k IWATE MEDICAL UNIVERSITY   (Japan)

^l SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Bromocriptine; Dopamine agonists; Levodopa; Parkinson s disease

Indexed keywords

AMANTADINE; BROMOCRIPTINE; LEVODOPA;

ADULT; AGED; CONFERENCE PAPER; FEMALE; HUMAN; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL;

BROMOCRIPTINE; COMPARATIVE STUDY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMAN; LEVODOPA; LONG-TERM CARE; MOTOR SKILLS; NEUROLOGIC EXAMINATION; PARKINSON DISEASE;

EID: 0025911459     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000116716     Document Type: Article

References (13)

1. Nakanishi T., Mizuno Y., Goto I., Iwata M., Kanazawa I., Kowa H., Mannen T, Nishitani H., Ogawa N, Takahashi A, Tashiro K., Tohgi H, Yanagisawa N: A nationwide collaborative study on the longterm effects of bromocriptine in patients with Parkinson’s disease. First interim report in Japan. Eur Neurol 1988;28suppl 1:3-8.
2. Teychenne PE. Bergrud D. Racy A. Elton RL. Vern B: Bromocriptine: Low dose therapy in Parkinson’s disease. Neurology 1982; 32:577-583.
3. Nakanishi T, Iwata M, Goto I, Kanazawa I. Kowa II. Mannen T. Mizuno Y. Nishitani H. Ogawa N, Takahashi A, Tashiro K, Tohgi H. Yanagisawa N: Second interim report of the nationwide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. Eur Neurol 1989;29suppl 1:3-8.
4. Nakanishi T., Kanazawa I., Goto I., Iwata M., Kowa H, Mannen T., Mizuno Y, Nishitani II., Ogawa N, Takahashi A., Tashiro K., Tohgi H., Yanagisawa N: Third interim report of the nationwide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. Eur Neurol 1990;30suppl 1:3-8.
5. Grimes JD. Delgado MR: Bromocriptine: Problems with low-dose de novo therapy in Parkinson’s disease. Clin Neuropharmacol 1985;8:73-77.
6. Hely MA., Morris JGL., Rail D., Reid WC.J., O’Sullivan DJ., Williamson PM., Genge S.: The Sydney multicenter study of Parkinson’s disease: A report on the first 3 years. J Neurol Neurosurg Psychiatry 1989:52:324-328.
7. Lees AJ. Stern GM: Sustained bromocriptine therapy in previously untreated patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1981:44:1020-1023.
8. Rascol A., Montastruc, IL., Guiraud-Chaumeil B., Clanet M: La bromocriptine comme premier traitement de la maladie de Parkinson. Rev Neurol 1982:138:401-108.
9. Rascol A., Montastruc JL, Rascol O: Should dopamine agonists be given early or late in the treatment of Parkinson’s disease? Can J Neurol Sci 1984; 1 suppl:229-232.
10. Rinne UK: Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease. Neurology 1987:37:826-828.
11. Rinne UK: Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson’s disease. Lancet 1981;1:33.
12. Demonet JF, Rostin M., Dueymes JM., loualalen A., Montastruc JL., Rascol A: Retroperitoneal fibrosis and treatment of Parkinson’s disease with high doses of bromocriptine. Clin Neuropharmacol 1986:9:200-201.
13. Grimes JD: Bromocriptine in Parkinson’s disease: Results obtained with high and low dose therapy. Can J Neurol Sci 1984: 11:225-228.